pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
PUBLIC COMPANY
save

$AURAAura Biosciences, Inc.

$AURA
Boston, MA, USupdated 18d ago
Website ↗SEC EDGAR ↗Yahoo Finance ↗
community read0 votes
pipeline
1
marketed
0
phase 3
1
catalysts ytd
0
approvals ytd
0
recalls ytd
0

Pipeline(1)

pipeline depth1 products
Phase 3: 1
1Phase 3
Phase 3
belzupacap sarotalocan
Uveal Melanoma

📅 Upcoming

no upcoming catalysts on record

🕒 Recent(90d)

nothing in the last 90 days
view all catalysts →

Active trials

  • phase1A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder Cancerrecruitingn=55
  • phase2Suprachoroidal Administration in Subjects With Metastases to the Choroidrecruitingn=24
  • phase3A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanomarecruitingn=100
  • —Choroidal Melanoma Patient-Reported Outcome Study (CM-PRO) in a Subset of AU-011-301 (CoMpass) Subjectsrecruitingn=15
  • —A Long-Term Follow-Up Study of Subjects Completing the AU-011-301(CoMpass) for Early Choroidal Melanomanot yet recruitingn=100
  • phase2Phase 2 Trial to Evaluate Belzupacap Sarotalocan (AU-011) Via Suprachoroidal Administration in Subjects With Primary Indeterminate Lesions and Small Choroidal Melanomacompletedn=22
  • phase2Study in Subjects With Small Primary Choroidal Melanomacompletedn=57
  • —A Registry of Subjects With Primary Indeterminate Lesions or Choroidal Melanomarecruitingn=500
more trials →

Insider activity

source: SEC Form 4

open-market buys + sells

  • Apr 16, 26SELLKilroy Conor· See Remarks11,738 sh @ $7.02−$82K↗
routine RSU / option mechanics (6)
  • Mar 2, 26grantKilroy Conor · See Remarks62,339 sh
  • Mar 2, 26grantKilroy Conor · See Remarks112,661 sh
  • Mar 2, 26grantGibney Anthony S · See Remarks71,245 sh
  • Mar 2, 26grantGibney Anthony S · See Remarks128,755 sh
  • Mar 2, 26grantde los Pinos Elisabet · See Remarks166,000 sh
  • Mar 2, 26grantde los Pinos Elisabet · See Remarks249,000 sh
🐶 Hiring Signal
No open roles indexed yet — view Aura Biosciences, Inc. jobs →

News

  • Aura lays off 20% of workforce, rejigs C-suite amid R&D refocus on eye cancer
    Aura Biosciences is refocusing under its recently installed CEO, laying off 20% of its employees and overhauling its C-suite as it narrows its focus on ocular oncology.
    fiercebiotech · 6d ago
identifiers
ticker
$AURA
SEC CIK
0001501796
country
US
source
sec_tickers
top tags
Oncology1
mentioned in
1news items
entity-linker matched
Data sources
SEC EDGAR
last refreshed 7m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?